Giant Biogene Holding Co., Ltd. reported no changes to its share capital for the month ended 30 September 2026, according to its latest filing with Hong Kong Exchanges and Clearing Limited.
Authorised and Issued Share Capital • Authorised share capital remained at 5.00 billion ordinary shares with a par value of USD 0.00001 each, representing total authorised capital of USD 50,000. • Issued share count was unchanged at 1.06 billion ordinary shares, and the company held no treasury shares. Consequently, total issued share capital also stayed flat.
Public Float Compliance Giant Biogene confirmed compliance with the Main Board’s minimum public float requirement of 25%, ensuring adequate share liquidity in the market.
Share Option Scheme Activity • Under the 2023 Share Option Scheme (adopted 17 August 2023), 10.93 million options were outstanding both at the beginning and end of September. • No options were exercised during the month; therefore, no new shares were issued and no treasury shares were transferred. • The scheme still permits issuance of up to 80.89 million additional shares upon future option exercises.
Other Equity Instruments The company reported no warrants, convertible securities, or other agreements that could dilute the share base, and there were no share repurchases, cancellations, or treasury share movements in September.
Governance Confirmation Executive Director and Joint Company Secretary Yan Yubo affirmed that all disclosures comply with Hong Kong Listing Rules, with requisite authorisations and regulatory filings in place.
Overall, Giant Biogene’s September 2026 return highlights a steady capital position, with consistent share counts, full public float compliance, and no dilutive events during the period.
Comments